Nachrichten und Videos - PULMATRIX INC. - Seite 2

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update PR Newswire LEXINGTON, Mass., May 12, 2022 Ends Q1 with $47.5 million in cash and cash equivalents; Extends cash runway into Q2 2024 LEXINGTON, Mass. , May 12, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced...

Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update PR Newswire LEXINGTON, Mass., March 29, 2022 LEXINGTON, Mass. , March 29 , 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced fourth quarter and year-end financial results for 2021 and provided a corporate update....

Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD PR Newswire LEXINGTON, Mass., March 21, 2022 LEXINGTON, Mass. , March 21, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced positive top-line results of its recently completed Phase 1b clinical study of...

Pulmatrix Regains Compliance With Nasdaq Listing Requirements PR Newswire LEXINGTON, Mass., March 17, 2022 LEXINGTON, Mass. , March 17, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced that it received written notice from the Nasdaq Listing Qualifications Staff of the NASDAQ Stock Market LLC...

Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline PR Newswire LEXINGTON, Mass., March 1, 2022 LEXINGTON, Mass. , March 1, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, announced the hiring of Dr. Margaret Wasilewski as the Company's Chief Medical Officer effective March 1...

Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split PR Newswire LEXINGTON, Mass., Feb. 24, 2022 LEXINGTON, Mass. , Feb. 24, 2022 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM) a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced a 1-for-20 reverse split of its common stock, to be effective as of 4:05 p.m. Eastern Time on...

Pulmatrix Issues Letter to Stockholders PR Newswire LEXINGTON, Mass., Feb. 1, 2022 LEXINGTON, Mass. , Feb. 1, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, issued the following letter to stockholders from Chief Executive Officer Ted Raad . Pulmatrix Letter to Stockholders – 2021 Review and 2022 Outlook To the...

Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering PR Newswire LEXINGTON, Mass., Dec. 17, 2021 LEXINGTON, Mass. , Dec. 17, 2021 /PRNewswire/ -- Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix" or the "Company"), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced that it has closed its previously announced registered direct offering with...

Pulmatrix Announces $6.75 Million Registered Direct Offering PR Newswire LEXINGTON, Mass., Dec. 15, 2021 LEXINGTON, Mass. , Dec. 15, 2021 /PRNewswire/ -- Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix" or the "Company"), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced that it has entered into a definitive agreement with certain institutional investors...

Pulmatrix Reports Third Quarter 2021 Financial Results and Provides Business Update Pulmazole contract dispute with Cipla resolved, expect to initiate Pdivb study in Q1 2023 for treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) PUR3100 (Acute Migraine Product) IND submission planned for Q1 2022 with Pdiv study start anticipated in Q2 2022 PUR1800 (Acute Exacerbation in COPD Product) Pdivb study on track for top-line data in Q1 2022 PR Newswire LEXINGTON, Mass., Nov. 10, 2021 LEXINGTON,...

Pulmatrix Announces Resolution of Contract Dispute with Cipla PR Newswire LEXINGTON, Mass., Nov. 9, 2021 LEXINGTON, Mass. , Nov. 9, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced that it has completed an amendment to Pulmatrix's agreement with Cipla Technologies, LLC ("Cipla") for the development...

Pulmatrix Reports Second Quarter 2021 Financial Results and Provides Business Update PUR1800 Phase 1b study is fully enrolled with data anticipated in Q1 2022 PUR1800 6-month rat and 9-month dog toxicology data may enable expansion to chronic conditions PUR3100 Phase 1/ Phase 2 clinical study in acute migraine treatment on-track for start in Q1 2022 Projected cash runway extends beyond PUR1800 Phase 1b Q1 2022 and PUR3100 Phase 1 / Phase 2 Q4 2022 data milestones PR Newswire LEXINGTON, Mass.,...

Pulmatrix appoints Director Anand Varadan PR Newswire LEXINGTON, Mass., July 27, 2021 LEXINGTON, Mass. , July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced the appointment of Anand Varadan to its Board of Directors, effective July 26, 2021. Mr. Varadan brings expertise in commercialization...

Pulmatrix Reports First Quarter 2021 Financial Results and Provides Business Update PUR1800 Phase 1b data anticipated in Q4 2021 Phase 1/ Phase 2 Study for PUR3100 in acute migraine treatment on-track for study start in Q1 2022 Cash runway extends beyond anticipated PUR1800 Pdivb and PUR3100 Pdiv/Pdiv data milestones Pulmatrix seeks reaffirmation of 50/50 partnership from Cipla Technologies PR Newswire LEXINGTON, Mass., May 11, 2021 LEXINGTON, Mass. , May 11, 2021 /PRNewswire/ -- Pulmatrix, Inc....

Pulmatrix Hosting Key Opinion Webinar on PUR3100 (Orally Inhaled DHE) Therapy for the Treatment of Acute Migraine PR Newswire LEXINGTON, Mass., April 15, 2021 LEXINGTON, Mass. , April 15, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced that it will host a key opinion leader (KOL) webinar on...

Corrected: Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio Termination of License, Development and Commercialization Agreement with the Lung Cancer Initiative at Johnson & Johnson will Return Portfolio to Pulmatrix Pulmatrix to continue development of PUR1800 for treatment of Acute Exacerbations in Chronic Obstructive Pulmonary Disease (AECOPD) with Phase 1b Study Ongoing with Data Expected Q4 2021 Long-term Toxicology Data in Q3 2021 has Potential to...

Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio Termination of License, Development and Commercialization Agreement with the Lung Cancer Initiative at Johnson & Johnson will Return Portfolio to Pulmatrix Pulmatrix to continue development of PUR1800 for treatment of Acute Exacerbations in Chronic Obstructive Pulmonary Disease (AECOPD) with Phase 1b Study Ongoing with Data Expected Q4 2021 Long-term Toxicology Data in Q3 2021 has Potential to Broaden...

Pulmatrix Reports 2020 Financial Results and Provides Business Update Initiated PUR1800 Phase 1b study with data anticipated in Q4 2021 Pulmazole Pdivb study start anticipated Q1 2022 PUR3100 development candidate declared for pulmonary delivered DHE (dihydroergotamine) acute migraine treatment Cash runway extends beyond all anticipated PUR1800 Pdivb, PUR3100 Pdiv/Pdiv, and Pulmazole Pdivb data milestones PR Newswire LEXINGTON, Mass., March 23, 2021 LEXINGTON, Mass. , March 23, 2021 /PRNewswire/...

Pulmatrix Provides a Pipeline and Business Update PUR1800 Phase 1b study dosing is underway with data anticipated in Q4 2021 Pulmatrix completed FDA Type-C meeting and anticipates a Pulmazole Pdivb study start in Q1 2022 PUR3100 lead DHE (dihydroergotamine) formulation identified for pulmonary delivered acute migraine treatment Cash runway extends beyond anticipated PUR1800 Pdivb, PUR3100 Pdiv/Pdiv and Pulmazole Pdivb data milestones PR Newswire LEXINGTON, Mass., March 4, 2021 LEXINGTON, Mass. ,...

Pulmatrix Announces Closing of $40 Million Registered Direct Offering PR Newswire LEXINGTON, Mass., Feb. 16, 2021 LEXINGTON, Mass. , Feb. 16, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced that it has closed its previously announced registered direct offering with certain healthcare-focused...